The assay evaluates a patient's tumor immune profile against Cofactor's high-dimensional RNA-based Health Expression Models to predict a patient's therapy response.

In an open letter, the organization called on Danaher and its subsidiary Cepheid to further lower the price of its Xpert MTB/RIF Ultra tuberculosis test.

In an open letter, the organization called on Danaher and its subsidiary Cepheid to further lower the price of its Xpert MTB/RIF Ultra tuberculosis test.

Retirements and the outcomes of a handful of close races could reshape congressional committees tasked with oversight of issues important to labs.

The field's rapid advances make securing reimbursement an important area of focus, researchers in a recent commentary argued.

Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.

Hong Kong-based Prenetics, which had a 50 percent stake in Insighta, sold some of its secondary shares and will now hold a 35 percent stake in the company.

The Maryland-based firm reported in a recent proof-of-concept study that It used protease biomarkers to identify patients ...

Aspira can now offer the test, intended for assessing ovarian cancer risk in women with an adnexal mass, to patients in New York state.

The firm's total revenues increased 5 percent year over year, leading it to raise the midpoint of its full-year EPS guidance.

The firm's analysts wrote that they see stability in Revvity's diagnostics business and growth above peers in its life sciences and reagents business.

Last week, readers were most interested in a story about Roche and BARDA teaming up to develop diagnostic tests for traumatic brain injuries.